China Medical Technologies, Inc. (NASDAQ:CMED) is a China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic ("IVD") products using Enhanced Chemiluminescence ("ECLIA") technology, Fluorescent in situ Hybridization ("FISH") technology and Surface Plasmon Resonance (“SPR”) technology to detect and monitor various diseases and disorders.In February 2012, the company's shares moved from the NASDAQ to the pink sheet in the United States.